Our man in Russia....a glimpse at the international nature of clinical research

A few years ago, we had the opportunity to host a 27-year old Russian oncologist in Oregon. This was a part of an international exchange sponsored by our professional society, ASCO.  Young oncologists from around the world were hosted by American institutions for a week to get some experience with research conducted in the US.  Who would have thought that our guy, Ilya Tsimafeyeu would become the CEO of RUSSCO, the Russian counterpart to ASCO, the American Society of Clinical Oncology.  

It was fun to see a recently interview with Ilya, or shall I say, the CEO.  Take a look at it here if you would like a glimpse of how things are going in Russia.

To put a smile on your face see Larry's latest cartoon.
To learn more about clinical trials, take a look at our book.

(c) 2012 Tom Beer and Larry Axmaker

Video: abiraterone and enzalutamide for advanced prostate cancer: results from ASCO 2012 discussed

A video summary of the most important data regarding abiraterone (Zytiga ®) and enzalutamide (MDV-3100) - two of the most important new drugs in prostate cancer.  Recorded at ASCO 2012.

To put a smile on your face see Larry's latest cartoon.
To learn more about clinical trials, take a look at our book.

(c) 2012 Tom Beer and Larry Axmaker

ASCO 2012 Update on advanced prostate cancer treatment

ASCO is the world's largest oncology meeting.  Important new data about abiraterone and MDV-3100 were presented at the meeting.  Both of these drugs have been shown to have a significant benefit for patients with metastatic prostate cancer that is resistant to standard hormonal therapy.


I had the privilege of reviewing the latest developments in treatment of advanced prostate cancer.  The slides for my talk are available here.  It's a large file, so be sure you have a broad band connection to download.  The slides are fairly technical at times, but do include "current status" summary slides that provide a succinct summary of the status of each of the new agents discussed.


To put a smile on your face see Larry's latest cartoon.

To learn more about clinical trials, take a look at our book.
(c) 2012 Tom Beer and Larry Axmaker